Things you must know about LDN therapy
Naltrexone is an opioid receptor blocker, which in 1984
was approved by the FDA for treating opioid addiction. “Low dose” basically
refers to the utilization of a daily dose that is about 1/10th of the dose
typically given for the treatment of opioid addiction. At such lower doses, the
medicine acts differently, presenting anti-inflammatory responses and useful
influences on the immune system. LDN has been clinically used since the late
19s, but there was no general attention given to its various therapeutic applications
until more recently.
Low-dose naltrexone had its very first
human trial conducted in 2007, and since that time, it has been proved
beneficial for the treatment of various medical conditions. Effectiveness in
treating fibromyalgia, multiple sclerosis, Crohn’s, and lupus have been
recorded in a number of clinical studies. Many different conditions might
benefit from the positive outcomes low-dose naltrexone has on the immune
system, and many new therapeutic applications are continuing to be
investigated.
The conditions that can be managed using LDN are various,
and doctors have been utilizing it as an alternative treatment option for many
years. It is evident that LDN can treat chronic diseases such as Crohn’s,
fibromyalgia, multiple sclerosis, and degenerative brain disorders such as
Alzheimer’s and Parkinson’s, immune system diseases, and numerous other
conditions. Since the production of endorphins is bound with the immune system
and several mechanisms of the body, many diseases can likely benefit from low-dose naltrexone. LDN continues to be
investigated even while healthcare providers prescribe it regularly for the
therapeutic effects they see in patients.
LDN inhibits receptors for just a few hours, and after
that, it is excreted. The lower dose of naltrexone acts as an inducer of the
“rebound” effect that continues for nearly one day. But with higher doses, this
effect cannot be obtained. Once the medicine is excreted from the body, the
sensitized receptors are capable of utilizing the increased endorphins in a
better way. Low-dose naltrexone results in more
efficient utilization and better production of OGF.
● Liquid Oral Liquid Formulation: 1mg/1ml is the most
ordinarily used form of low-dose naltrexone in the UK. It is
daily taken and administered using a baby oral syringe. This formulation does
not include high amounts of lactose or any different excipient that can cause
hypersensitivity. The base used is similar to the one used in children’s cough
syrup, making it quite palatable. Because only a few preservatives are added,
the formulation must be kept in the fridge. It lasts for almost three months if
stored properly.
● Capsules: For people who cannot take liquid or find it
undesirable, capsules are available in different strengths ranging from 1.5mg,
3mg, and 4.5mg, as well as additional specific doses. Be sure to mention that
you do NOT wish to take LDN in a slow-release form. Pharmacies must be notified
NOT to give low-dose naltrexone in an SR/slow-release/timed-release form.
Unless the low dose of naltrexone is in an unchanged form, which allows it to
attain a prompt “peak” in the bloodstream, its therapeutic results might be
inhibited. Capsules of LDN significantly contain a large percentage of inactive
filler. Attempts by Dr. Skip Lenz have confirmed that the use of calcium
carbonate filler will intervene with the capsule’s absorption. Consequently, it
is recommended that calcium carbonate filler should NOT be incorporated into
the LDN capsules. He suggests either Avicel, lactose (in the case lactose
intolerance is not an issue), or sucrose fillers as valuable fast-release
fillers. Make sure to get your prescription filled by a compounding pharmacy,
such as Harbor Compounding Pharmacy, that has a we-established name for
reliability in providing the quality of the low dose of naltrexone it delivers.
● Sublingual Drops: Sublingual drops are produced for
patients who face problems taking medicine orally or for patients who want to
ensure the quickest delivery of the medicine into their bloodstream. The
quantity of drops is placed beneath the tongue using a dropper bottle, and the
dosage is raised and lowered by the number of drops used. There are no
excipients used in this formulation.
● Cream LDN: Cream in 0.5mg/ml or even higher is available
for application on the skin. This is appropriate for children or people who are
allergic to colorants, flavors, or any excipients in other formulations of LDN.
It is usually the most expensive dosage form.
Your physician will often begin treatment at an ultra-low dose of naltrexone and raise
this slowly over weeks – until you become stable and free of side effects. The
starting dosage can range from 0.5mg to 1.5mg – and is normally increased over
4 to 8 weeks to 4.5mg or even higher. Some physicians might even increase the
dose to twice daily for specific medical conditions. For Autoimmune Diseases, subjects
normally begin at 1mg/1.5mg and rise to 4.5mg every day over 4 to 8 weeks. But,
for Chronic Fatigue Syndrome, Hashimoto’s, or Fibromyalgia, the recommended
starting dose is normally 0.5mg to 1.0mg, and then it is raised by 0.5mg every
week until the dose of 4.5mg is maintained. For Cancer, LDN can be used at
similar doses, but it must not be used a week before and one week following
cancer chemotherapy.
Reference article link:
https://vocal.media/psyche/things-you-must-know-about-ldn-therapy
